When assessing young people for potential early psychosis, psychiatrists should keep in mind that reassurance is particularly important for this patient group, explained Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
When assessing young people for potential early psychosis, psychiatrists should keep in mind that reassurance is particularly important for this patient group, explained Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
Transcript
How should a psychiatrist conduct an assessment of potential early psychosis in a young person?
When a psychiatrist is meeting someone with early psychosis for the first time, there are a couple of issues. In addition to sort of the traditional mental health status exam, reviewing the symptoms, there are also key issues around reassurance and comfort level. For many young people who are facing a question of a psychotic illness, there’s a great deal of fear, there may be paranoia, there’s worry about “Am I going crazy? Is my brain playing tricks on me?”, so reassurance is important. Helping a young person understand that, even if they are developing psychotic symptoms, that by virtue of coming in for early care they can have a really positive outcome, is a very important piece, and for many of us as psychiatrists, that view’s not been part of our training. So, in addition to sort of the traditional evaluation, a really great history, looking at family history, the reassurance is important.
Another issue for adolescents also is that when someone develops a psychotic process, we may not know for a few years whether this will be a schizophrenia spectrum illness, a bipolar issue, depression with psychotic features, and so it’s important not to maybe rush to a diagnostic conclusion too early in the process.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More